Make the profile of
Converge Bio yours.

Company description

Converge Bio develops Generative AI solutions for biotech and pharmaceutical companies, with a focus on accelerating drug discovery and development. The company trains large language models (LLMs) on core biological languages — DNA, RNA, and protein sequences — and builds experimentally validated tools around these models that are designed to be accessible to working scientists at any stage of the drug discovery lifecycle.

Rather than delivering standalone predictions or benchmark results, Converge Bio positions itself as an AI-lab partner, working in a closed loop with customer teams until solutions are wet-lab validated and development-ready. The company's platform is built on proprietary AI models and technology developed in-house, each optimized for different stages of drug development.

Key Solution Areas

• Target Discovery: AI-supported systems to help scientists identify and prioritize drug targets.
• Antibody Design: Generative AI tools to support the design of antibody candidates.
• Protein Manufacturing Optimization: Solutions aimed at improving the efficiency and outcomes of protein production processes.
• Biomarker Discovery: AI-driven approaches to identify relevant biomarkers within drug development programs.

Platform and Approach

• Models are trained specifically on biological sequence languages, including DNA, RNA, and protein sequences.
• All solutions are built around experimentally validated outputs, with wet-lab validation treated as the primary measure of success rather than computational benchmarks alone.
• The platform is designed so that scientists across a customer organization can use the tools directly, without requiring deep AI expertise.
• Converge Bio operates as an ongoing partner rather than a one-time vendor, maintaining a collaborative relationship with customer teams through the validation process.

Mission and Customer Focus

• The company's stated goal is to provide a dedicated AI solution for scientists at every stage of the drug discovery lifecycle.
• Primary customers are biotech and pharmaceutical companies seeking to discover and develop more effective drugs more quickly.
• The company emphasizes a "solutions first" approach, with its platform built around proprietary in-house technology rather than third-party models adapted for life sciences use.

AI-generated · replace with your own

Software attributed to Converge Bio

• Patent ExtractorView
• Antibody SearchView

Edit all with premium access